6天6阳，港股通医疗、港股通创新药正加速回暖！

Group 1 - The Hong Kong stock market for pharmaceuticals and healthcare has shown a strong upward trend since February, with notable performance from ETFs such as the Hong Kong Innovation Drug ETF (520880) and the Hong Kong Healthcare ETF (159137), both achieving six consecutive days of gains [1] - The total transaction scale for China's innovative drug License-out is projected to reach a record $135.7 billion by 2025, with significant collaborations occurring in early 2026, validating the global value of domestic innovative drug pipelines [1] - The Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," indicating a shift towards commercial realization of pipeline expectations, with many quality stocks showing attractive valuation ratios [1] Group 2 - The Hong Kong Innovation Drug ETF (520880) and its associated fund (025221) focus entirely on innovative drug research and development companies, with the top ten weighted stocks accounting for over 73% of the portfolio, highlighting its leading attributes [2] - The Hong Kong Healthcare ETF (159137) targets medical innovation, encompassing trending concepts such as brain-computer interfaces, AI healthcare, and online pharmacies, while also covering leading companies across the entire innovative drug industry chain [2]